Advertisement

Search Results

Advertisement



Your search for Ruth M. O'Regan, MD,Ruth M. O'Regan, MD matches 3 pages

Showing 1 - 3


breast cancer

Breast Cancer 2022–2023 Almanac

The past year has been an exciting time for breast oncologists and patients with all stages of breast cancer, with new agents approved and long-term results from pivotal trials showing improved survival for patients with metastatic disease. Let’s take a look at some of the highlights in early-stage ...

breast cancer

Adding Everolimus to First-Line Trastuzumab/Paclitaxel Does Not Increase Progression-Free Survival in HER2-Positive Metastatic Breast Cancer

In the phase III BOLERO-1 trial, reported in The Lancet Oncology, Sara A. Hurvitz, MD, of the University of California, Los Angeles, and colleagues found that the addition of the mTOR inhibitor everolimus (Afinitor) to trastuzumab (Herceptin)/paclitaxel did not significantly increase...

breast cancer

Andrew Seidman, MD, and Ruth O'Regan, MD: Update on Early Breast Cancer

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Ruth M. O’Regan, MD, of the University of Wisconsin, review practice-changing research in 2015 that was focused on early-stage breast cancer.

Advertisement

Advertisement




Advertisement